doxorubicin,sotigalimab
apexigen
['doxorubicin', 'apex', 'sotigalimab', 'sarcoma', 'apexigen']
apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of clinical oncology (asco) 2023 annual meeting - health... 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2